详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Targeting PRAME for acute myeloid leukemia therapy

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China. [2]Department of Dermatology and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

出处：

DOI：

关键词： PRAME acute myeloid leukemia leukemia-associated antigen minimal residual disease immunotherapy adoptive T-cell therapy

摘要：

Despite significant progress in targeted therapy for acute myeloid leukemia (AML), clinical outcomes are disappointing for elderly patients, patients with less fit disease characteristics, and patients with adverse disease risk characteristics. Over the past 10 years, adaptive T-cell immunotherapy has been recognized as a strategy for treating various malignant tumors. However, it has faced significant challenges in AML, primarily because myeloid blasts do not contain unique surface antigens. The preferentially expressed antigen in melanoma (PRAME), a cancer-testis antigen, is abnormally expressed in AML and does not exist in normal hematopoietic cells. Accumulating evidence has demonstrated that PRAME is a useful target for treating AML. This paper reviews the structure and function of PRAME, its effects on normal cells and AML blasts, its implications in prognosis and follow-up, and its use in antigen-specific immunotherapy for AML.Copyright © 2024 Yang, Chen, Ye and Ma.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 2 区医学

小类 | 2 区免疫学

第一作者：

第一作者机构： [1]Department of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]CAR-NK cells for acute myeloid leukemia immunotherapy: past, present and future [2]Glycolysis and chemoresistance in acute myeloid leukemia [3]Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis [4]Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire [5]Structural maintenance of chromosomes 4 is required for leukemia stem cell maintenance in MLL-AF9 induced acute myeloid leukemia. [6]Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia [7]Chimeric Antigen Receptor T Cells Targeting Cell Surface GRP78 to Eradicate Acute Myeloid Leukemia [8]FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N-6-Methyladenosine RNA Demethylase [9]Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia. [10]Advances in Drug Delivery Systems for the Treatment of Acute Myeloid Leukemia